Successful immunotherapy with PD-1 Iinhibitor for advanced pancreatic cancer: report of two cases and review of literature

医学 胰腺癌 免疫疗法 肿瘤科 腺癌 癌症 内科学 化疗 进行性疾病 癌症研究
作者
Lijie Qiu,Chen Liu,Heping Li
出处
期刊:Anti-Cancer Drugs [Lippincott Williams & Wilkins]
卷期号:35 (3): 263-270 被引量:3
标识
DOI:10.1097/cad.0000000000001546
摘要

Pancreatic cancer is a highly malignant tumor, and most patients are diagnosed at an advanced stage. Unfortunately, due to the immunosuppressive tumor microenvironment of pancreatic cancer, the benefits of immunotherapy for patients with advanced pancreatic cancer are still unclear. Here, we present two cases of advanced pancreatic cancer being controlled by immunotherapy, with pathological diagnoses of ductal adenocarcinoma and acinar cell carcinoma, respectively. Next-generation sequencing (NGS) of both patients is high tumor mutation burden (tumor mutation burden—High) and microsatellite stable. The patient with pancreatic ductal adenocarcinoma was diagnosed as a locally advanced disease (stage III). She received irreversible electroporation, used the programmed death receptor-1 (PD-1) inhibitor (pembrolizumab) combined with chemotherapy (S-1), and then used only the PD-1 inhibitor as a maintenance treatment. As a result, the patient’s lesion was significantly reduced, with a partial response time of up to 31 months. The patient with acinar cell carcinoma was diagnosed as a metastatic disease (stage IV), next-generation sequencing revealed mutations in SMAD4 and KMT2D, and two chemotherapy regimens were used unsuccessfully. Then, the combination of chemotherapy with PD-1 (tislelizumab) and vascular endothelial growth factor/vascular endothelial growth factor receptor (anlotinib) inhibitors were used, and the lesions of the patient were significantly reduced, and the progression-free survival after immunotherapy was 19 months. In advanced pancreatic cancer, a prognosis of this magnitude is rare. Our cases reveal the potential of immunotherapy as a cornerstone treatment in the management of advanced pancreatic cancer.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
3秒前
6秒前
琦琦完成签到,获得积分10
8秒前
落后若云发布了新的文献求助10
9秒前
9秒前
大飞发布了新的文献求助10
10秒前
笑点低的达完成签到,获得积分10
11秒前
husiqi_547发布了新的文献求助10
13秒前
13秒前
ySX应助julia采纳,获得10
13秒前
没招了没招了关注了科研通微信公众号
14秒前
风格发布了新的文献求助50
15秒前
JamesPei应助qianye采纳,获得10
16秒前
秦何完成签到,获得积分10
16秒前
我是老大应助tsy123_采纳,获得10
17秒前
Joel完成签到 ,获得积分10
17秒前
张婷完成签到,获得积分10
17秒前
洁净的雨柏完成签到,获得积分10
19秒前
lualong完成签到,获得积分10
22秒前
周至发布了新的文献求助10
24秒前
mimi完成签到 ,获得积分10
24秒前
24秒前
24秒前
好了完成签到,获得积分10
25秒前
我是小汪应助yzm采纳,获得10
25秒前
哈哈哈哈完成签到,获得积分10
26秒前
27秒前
27秒前
欧斌完成签到,获得积分10
27秒前
Huyyy完成签到,获得积分10
27秒前
28秒前
28秒前
云嘉懿完成签到,获得积分20
29秒前
乐乐应助julia采纳,获得10
29秒前
29秒前
丁旺完成签到,获得积分10
30秒前
30秒前
Akim应助茉莉花采纳,获得10
30秒前
qianye发布了新的文献求助10
31秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Salmon nasal cartilage-derived proteoglycan complexes influence the gut microbiota and bacterial metabolites in mice 2000
The Composition and Relative Chronology of Dynasties 16 and 17 in Egypt 1500
Picture this! Including first nations fiction picture books in school library collections 1500
ON THE THEORY OF BIRATIONAL BLOWING-UP 666
Signals, Systems, and Signal Processing 610
The Impostor Phenomenon: When Success Makes You Feel Like a Fake 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 物理 内科学 复合材料 催化作用 物理化学 光电子学 电极 细胞生物学 基因 无机化学
热门帖子
关注 科研通微信公众号,转发送积分 6377792
求助须知:如何正确求助?哪些是违规求助? 8190862
关于积分的说明 17303282
捐赠科研通 5431389
什么是DOI,文献DOI怎么找? 2873421
邀请新用户注册赠送积分活动 1850132
关于科研通互助平台的介绍 1695451